胰臟癌是高度惡性癌症，且其早期通常並無症狀，直至末期才有較顯著的臨床症狀，早期胰臟癌通常沒有明顯的症狀，之後也缺乏顯著或者確定的症狀，因此胰臟癌經常到晚期才能被正確診斷。由於症狀不明顯、診斷不易，再加上病程進展快速且無有效治療方式，使其五年存活率極低，故能早期診斷與治療是一大難題。國外多篇研究指出目前並沒有可用來篩選高危險胰臟癌患者的標準程序，在最近幾年中，已經有學者提出可大量使用於胰臟癌診斷的生物標誌物，但大多數缺乏大規模人體實驗驗證。因此，儘管具有診斷限制，CA 19-9仍是實際在臨床使用中唯一的胰臟癌生物標誌物。
巨量資料的時代已經來臨，如何將無時無刻產出的檢驗資料，藉由商業智慧分析工具將大量且複雜的數據進行切割、鑽取，並且能夠迅速產出有用及正確的資訊，提供臨床診斷與治療方向決策的依據，也是一大挑戰。
研究結果顯示， CA19-9異常數值分析發現以中老年人為主，男性略多於女性，分析CA19-9檢驗結果與胰臟癌分期及發生位置之關聯性，可以發現CA19-9檢驗結果值以胰臟體部腫瘤及第三期為最高。進一步分析胰臟癌發生位置、分期與存活時間之關係。可以發現胰臟尾部腫瘤及第三期的存活時間最長。根據以上的分析可以發現CA19-9檢驗數值對於胰臟癌診斷並無專一性，但若發現異常高值時，可合併CT、PET-CT或MRI等影像學工具輔助診斷，提高診斷準確率，以早期發現早期治療。
藉由這套線上即時分析系統，可以了解各科別甚至每位醫師開立CA19-9這個檢驗項目的數量，再結合病歷診斷來了解其開單是否符合臨床診斷需求，是否有被健保核刪風險，醫院經營管理者可以針對有核刪高風險的單位或個人提出改善建議，以降低健保核刪，得到所應得的健保給付，以利醫院永續經營。

(1) Scope and Objectives: Pancreatic cancer is a highly malignant cancer, and it is usually symptomless in the early stage, and only becomes clinically evident until the end phase of the disease course. The aim of this research is to construct a set of online analysis processing system based on the concept of business intelligence, we can analyze the diagnosis and prognosis of pancreatic cancer from different aspects, analyze the influence of different stages of pancreatic cancer, and explore the relationship between CA19-9 and survival time. (2) Methods: 812 CA19-9 abnormal results and diagnosis, were collected from a regional teaching hospital in the southern Taiwan from 2010 to 2012. The relationship between the variables was analyzed by chi-square test and independent T-test. Linear regression and support vector regression were used to analyze the prognosis of the patients. (3) Results: The risk of pancreatic cancer is increased in those patients with abnormal high CA19-9 value. Analysis of CA19-9 results and pancreatic cancer staging and location of the association, CA19-9 result can be found in the value of the pancreatic body tumor as the highest, the lowest for pancreatic head cancer. If the stage of pancreatic cancer, then the highest for the third period, the first phase of the lowest. (4) Conclusions: Based on the above analysis, we can found that CA19-9 values are not specific for the diagnosis of pancreatic cancer. If CA19-9 value is abnormal high, it can combine CT, PET-CT or MRI and other imaging tools to help diagnosis, and improve the diagnostic accuracy, In order to achieve the purpose of early diagnosis and early treatment.

一、中文部分
1. 翁慈宗（2009），資料探勘的發展與挑戰，科學發展 442 期，2009 年10 月。
2. 薛肇文（2004），血清腫瘤標記於大腸直腸癌預測模式之研究，義守大學管理研究所碩士論文。
3. 衛生福利部國民健康署資料開放平台（2015），104年死因統計結果分析（http://data.hpa.gov.tw/）。
二、英文部分
1. Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S. (2015)."Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. " HPB (Oxford). 17(10):942-952.
2. Audisio RA, Veronesi P, Maisonneuve P, Chiappa A, Andreoni B, Bombardieri E, Geraghty JG.(1996)."Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma." Surg Oncol.5(2):49-63.
3. Dranka-Bojarowska D, Lekstan A, Olakowski M, Jablonska B, Lewinski A, Musialski P, Sobczyk W, Kapalka A, Lampe P(2015). "The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis. " J Physiol Pharmacol. 66(5):653-663.
4. Haab BB, Huang Y, Balasenthil S, Partyka K, Tang H, Anderson M, Allen P, Sasson A, Zeh H, Kaul K, Kletter D, Ge S, Bern M, Kwon R, Blasutig I, Srivastava S, Frazier ML, Sen S, Hollingsworth MA, Rinaudo JA, Killary AM, Brand RE(2015). "Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. " PLoS One.10(10)
5. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P & Witten I H. (2009). "The WEKA data mining software: an update" SIGKDD Explor 11(1):10-18.
6. Honda K, Kobayashi M, Okusaka T, Rinaudo JA, Huang Y, Marsh T, Sanada M, Sasajima Y, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Miura N, Kamita M, Sakamoto T, Shoji H, Jung G, Srivastava S, Yamada T(2015)."Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. " Sci Rep. 9(5)
7. John L. Magnani, Zenon Steplewski, Hilary Koprowski, and Victor Ginsburg. (1983). "Identification of the Gastrointestinal and Pancreatic Cancer-associated Antigen Detected by Monoclonal Antibody 19-9 in the Sera of Patients as a Mucin1. " CANCER RESEARCH 43,(5489-5492).
8. Kamisawa T, Wood LD, Itoi T, Takaori K.(2016). "Pancreatic cancer. " Lancet. 388(10039):73-85.
9. Molina LM1, Díez M, Cava MT, Maestro ML, Ortega MD, Mendíz JG, Prego A, De Diego JA, Balibrea JL.(1990). "Tumor markers in pancreatic cancer: a comparative clinical study between CEA, CA 19-9 and CA 50. " Int J Biol Markers. 5(3):127-132.
10. Nakai Y, Isayama H, Sasaki T, Takahara N, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K.(2013). "A retrospective analysis of early CA19 9 change in salvage chemotherapy for refractory pancreatic cancer. " Cancer Chemother Pharmacol. 72(6):1291-1297.
11. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.(2005). "The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. " Eur J Surg Oncol. 31(2):164-169.
12. Ozkan H, Kaya M, Cengiz A.(2003). "Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. " Hepatogastroenterology. 50(53):1669-1674.
13. Pezzilli R, Billi P, Plate L, Laudadio MA, Sprovieri G.(1995). "Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA. " Ital J .astroenterol. 27(6):296-299.
14. Scarà S, Bottoni P, Scatena R(2003). "CA 19-9: Biochemical and Clinical Aspects. "Adv Exp Med Biol. 867:247-260.
15. Su SB, Qin SY, Chen W, Luo W, Jiang HX.(2015). "Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. "World J Gastroenterol.21(14).
16. Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF, Toskes PP. (1986). "Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. " Gastroenterology.90(2):343-349.
17. Vallejo J, Torres-Avisbal M, Contreras P, Rodríguez-Liñán M, Rebollo A, González F, Benítez A, Infante J, Mateo A (1999). "CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC analysis. " Rev Esp Med Nucl. 18(4):281-286.
18. Zhang Y, Jiang L, Song L. (2016). "Meta-analysis of diagnostic value of serum Carbohydrate antigen 199 in pancreatic cancer. " Minerva Med.107(1):62-69.